share_log

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

ProMIS Neurosciences和其他2只股票的執行官正在購買
Benzinga ·  09/19 21:17

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週三下跌超過100點。當內部人購買或賣出股票時，這表明他們對公司前景的信心或擔憂。對於對低價股感興趣的投資者和交易員來說，他們可以將這視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。

WidePoint

widepoint

  • The Trade: WidePoint Corporation (NYSE:WYY) CEO Jin Kang bought a total of 1,000 shares at an average price of $3.50. To acquire these shares, it cost around $3,499.
  • What's Happening: On Aug. 14, WidePoint posted a second-quarter GAAP loss of 5 cents per share.
  • What WidePoint Does: WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution.
  • 交易：WidePoint Corporation（紐交所：WYY）CEO Jin Kang以3.50美元的平均價格購買了總計1,000股。購買這些股票需要花費約3,499美元。
  • 正在發生的事情：8月14日，WidePoint發佈了第二季度按照美國通用會計準則計算的每股虧損爲5美分。
  • WidePoint Corp是提供科技管理服務（TMaaS）的供應商，包括聯邦認證的通信管理、身份管理、互動賬單呈現和分析以及信息技術服務解決方案。

ProMIS Neurosciences

ProMIS神經科學

  • The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) 10% owner Michael S Gordon acquired a total of 93,223 shares at an average price of $1.25. To acquire these shares, it cost around $116,880.
  • What's Happening: On Aug. 29, ProMIS Neurosciences filed for resale from time to time of 56.5 million common shares of the company by selling stockholders.
  • What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).
  • 交易：ProMIS Neurosciences，Inc.（納斯達克：PMN）的10％所有人Michael S Gordon以1.25美元的平均價格收購了總計93,223股。購買這些股票需要花費約116,880美元。
  • 動態: 8月29日，ProMIS神經科學公司通過出售股票股東，向日銷售5650萬普通股。
  • ProMIS神經科學做什麼：ProMIS神經科學公司是一家臨床階段的生物技術公司，專注於生成和開發選擇性靶向神經退行性疾病（如阿爾茨海默病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA））中有毒錯位蛋白的抗體治療藥物。

Emmaus Life Sciences

Emmaus生命科學

  • The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Director Seah H. Lim acquired a total of 20,000 shares at an average price of $0.04. The insider spent around $800 to buy those shares.
  • What's Happening: On Sept. 10, the company said net revenues for the six months ended June 30 were $7.9 million, down from $17.5 million in the year-ago period.
  • What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases.
  • 交易：Emmaus生命科學公司（OTC:EMMA）董事Seah H. Lim以平均價格0.04美元購入總共2萬股股票。這位內部人士花了約800美元買這些股票。
  • 動態: 9月10日，該公司表示截至6月30日的六個月淨收入爲790萬美元，低於去年同期的1750萬美元。
  • Emmaus生命科學公司業務範圍: Emmaus Life Sciences Inc是一家生物製藥公司，致力於發現、開發和商業化罕見和孤兒疾病的新治療方法和療法。
  • FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
  • 聯邦快遞準備啓動第一季度的印刷工作；以下是華爾街最準確分析師最近的預測變化

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論